Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr 25;6(4):e18462.
doi: 10.1371/journal.pone.0018462.

Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts

Catherine C McGowan  1 , David D Weinstein, Charles P Samenow, Samuel E Stinnette, Gema Barkanic, Peter F Rebeiro, Timothy R Sterling, Richard D Moore, Todd Hulgan
Affiliations

Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts

Catherine C McGowan et al. PLoS One. .

Abstract

Objective: Drug use and receipt of highly active antiretroviral therapy (HAART) were assessed in HIV-infected persons from the Comprehensive Care Center (CCC; Nashville, TN) and Johns Hopkins University HIV Clinic (JHU; Baltimore, MD) between 1999 and 2005.

Methods: Participants with and without injection drug use (IDU) history in the CCC and JHU cohorts were evaluated. Additional analysis of persons with history of IDU, non-injection drug use (NIDU), and no drug use from CCC were performed. Activity of IDU and NIDU also was assessed for the CCC cohort. HAART use and time on HAART were analyzed according to drug use category and site of care.

Results: 1745 persons were included from CCC: 268 (15%) with IDU history and 796 (46%) with NIDU history. 1977 persons were included from JHU: 731 (35%) with IDU history. Overall, the cohorts differed in IDU risk factor rates, age, race, sex, and time in follow-up. In multivariate analyses, IDU was associated with decreased HAART receipt overall (OR = 0.61, 95% CI: [0.45-0.84] and OR = 0.58, 95% CI: [0.46-0.73], respectively for CCC and JHU) and less time on HAART at JHU (0.70, [0.55-0.88]), but not statistically associated with time on HAART at CCC (0.78, [0.56-1.09]). NIDU was independently associated with decreased HAART receipt (0.62, [0.47-0.81]) and less time on HAART (0.66, [0.52-0.85]) at CCC. These associations were not altered significantly whether patients at CCC were categorized according to historical drug use or drug use during the study period.

Conclusions: Persons with IDU history from both clinic populations were less likely to receive HAART and tended to have less cumulative time on HAART. Effects of NIDU were similar to IDU at CCC. NIDU without IDU is an important contributor to HAART utilization.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2007. Vol. 19. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (2009). CDC website. Available: http://www.cdc.gov/hiv/surveillance/resources/reports/2007report/pdf/cov.... Accessed 1 April 2011.
    1. Centers for Disease Control and Prevention. Cases of HIV infection and AIDS in urban and rural areas of the United States, 2006. HIV/AIDS Surveillance Supplemental Report (2008). CDC website. Available: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2008supp_vo.... Accessed 1 April 2011.
    1. UNAIDS 2008 Report on the global AIDS epidemic. UNAIDS website. Available: http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/. Accessed 1 April 2011.
    1. Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004. PLoS One. 2009;4:e4445. - PMC - PubMed
    1. Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860. - PubMed

Publication types